In that study, mice treated with P2Y14 antagonists as well as mice lacking P2Y14 had decreased eosinophilia and airway hyperresponsiveness indicating that this receptor could be targeted to treat asthma exacerbations and glucocorticoid-resistant forms of asthma. This evidence concerns the gene P2RY14 and Increased total eosinophil count.